Hetrombopag Olamine
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Immune Thrombocytopenia
Conditions
Immune Thrombocytopenia
Trial Timeline
Jul 14, 2018 → Aug 17, 2018
NCT ID
NCT03603132About Hetrombopag Olamine
Hetrombopag Olamine is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Immune Thrombocytopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT03603132. Target conditions include Immune Thrombocytopenia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05944211 | Phase 2 | Recruiting |
| NCT03977805 | Phase 1 | Completed |
| NCT03603132 | Phase 1 | Completed |
| NCT03557099 | Phase 1/2 | Completed |
| NCT02614846 | Phase 1 | UNKNOWN |
| NCT02403440 | Phase 1 | UNKNOWN |
| NCT02409394 | Phase 1 | Completed |
Competing Products
20 competing products in Immune Thrombocytopenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pirtobrutinib + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Anti-(integrin beta-3) human monoclonal antibody | Rallybio | Phase 2 | 44 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Placebo + Lusutrombopag | Shionogi | Phase 2 | 52 |
| Lusutrombopag | Shionogi | Phase 2 | 52 |
| Romiplostim | Kyowa Kirin | Phase 1/2 | 41 |
| AMG 531 | Kyowa Kirin | Phase 2/3 | 65 |
| Romiplostim + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Romiplostim (AMG-531) | Kyowa Kirin | Phase 2 | 52 |
| Romiplostim and danazol | Kyowa Kirin | Phase 2 | 52 |
| SHR0302 quick release tablets + SHR0302 sustained-release tablets | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Hetrombopag + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| HR19042 Capsule, Tarpeyo®, Budenofalk® | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| HR19042 Capsules | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Herombopag | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Zostavax® | Merck | Pre-clinical | 23 |
| Raltegravir + Atazanavir | Merck | Pre-clinical | 23 |
| Zostavax | Merck | Pre-clinical | 23 |
| MK-8723 + Matching Placebo | Merck | Phase 1 | 33 |
| Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXM | Novartis | Phase 2 | 52 |